

Joseph H Antin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9396562/publications.pdf>

Version: 2024-02-01

198
papers

13,016
citations

34016

52
h-index

24915

109
g-index

315
all docs

315
docs citations

315
times ranked

11825
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2055-2066.	13.9	996
2	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , 2014, 123, 3664-3671.	0.6	730
3	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. <i>Blood</i> , 2004, 104, 579-585.	0.6	638
4	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	13.9	586
5	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
6	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.	0.6	403
7	Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2001, 19, 3685-3691.	0.8	396
8	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	0.8	359
9	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	0.8	339
10	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 3865-3874.	0.6	285
11	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	0.6	255
12	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. <i>Blood</i> , 2016, 127, 260-267.	0.6	245
13	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. <i>Blood</i> , 2012, 119, 1570-1580.	0.6	221
14	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
15	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010, 120, 1479-1493.	3.9	212
16	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
17	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	2.2	200
18	Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. <i>Blood</i> , 2003, 102, 2768-2776.	0.6	196

#	ARTICLE	IF	CITATIONS
19	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
20	Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. <i>Blood</i> , 2000, 96, 4096-4102.	0.6	191
21	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	0.6	179
22	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	0.6	178
23	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 130-137.	0.6	176
24	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	3.9	173
25	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. <i>Blood</i> , 2002, 100, 3479-3482.	0.6	167
26	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	0.6	156
27	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	0.6	145
28	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016, 127, 646-657.	0.6	145
29	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.	2.3	126
30	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	0.6	119
31	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011, 117, 2275-2283.	0.6	115
32	Comparative Outcomes of T-Cell-Depleted and Non-T-Cell-Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. <i>Journal of Clinical Oncology</i> , 1999, 17, 561-561.	0.8	108
33	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1238-1243.	2.0	108
34	ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. <i>Transfusion</i> , 1999, 39, 179-187.	0.8	101
35	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	0.6	101
36	Final results from a defibrotide treatment study for patients with hepatic venoocclusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018, 181, 816-827.	1.2	95

#	ARTICLE	IF	CITATIONS
37	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	0.6	92
38	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	0.6	92
39	Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review. <i>Stem Cells</i> , 2001, 19, 108-117.	1.4	89
40	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	0.6	88
41	Î±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	0.6	81
42	Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 1998, 91, 717-723.	0.6	80
43	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
44	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-201.	0.8	79
45	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. <i>Blood</i> , 2017, 130, 91-94.	0.6	78
46	Long-Term Care after Hematopoietic-Cell Transplantation in Adults. <i>New England Journal of Medicine</i> , 2002, 347, 36-42.	13.9	76
47	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. <i>Blood</i> , 2017, 129, 162-170.	0.6	75
48	Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 112-118.	1.2	72
49	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
50	Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1248-1251.	2.0	64
51	BK Virus Disease after Allogeneic Stem Cell Transplantation: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 564-570.	2.0	61
52	Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 213-222.	2.0	60
53	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 352-364.	2.5	58
54	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 873-880.	2.0	56

#	ARTICLE	IF	CITATIONS
55	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	0.6	56
56	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	1.2	53
57	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	2.3	53
58	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	2.5	52
59	Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 285-287.	2.0	51
60	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	48
61	Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 997-1004.	2.0	47
62	Up-Regulation of $\alpha 4 \beta 7$ Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1066-1076.	2.0	45
63	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
64	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019, 3, 2550-2561.	2.5	44
65	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 499-505.	1.7	43
66	Substance Abuse and Bone Marrow Transplant. <i>American Journal of Drug and Alcohol Abuse</i> , 1997, 23, 301-308.	1.1	38
67	Allotransplantation for Patients Age ≥ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
68	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	2.5	37
69	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
70	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
71	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
72	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59.	2.0	34

#	ARTICLE	IF	CITATIONS
73	Characterization of Oral Involvement in Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1717-1721.	2.0	33
74	The role of regulatory T cells in graft-versus-host disease management. <i>Expert Review of Hematology</i> , 2020, 13, 141-154.	1.0	33
75	Risk Factors for Readmission after Allogeneic Hematopoietic Stem Cell Transplantation and Impact on Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 509-516.	2.0	32
76	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 910-918.	2.0	32
77	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	1.7	31
78	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	0.6	30
79	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1808-1815.	2.0	29
80	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
81	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1251-1259.	1.7	27
82	ATG in allogeneic stem cell transplantation: standard of care in 2017? <i>Counterpoint. Blood Advances</i> , 2017, 1, 573-576.	2.5	27
83	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded access program. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27269.	0.8	25
84	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , 2020, 136, 3070-3081.	0.6	25
85	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 1222-1227.	1.7	24
86	Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1446-1451.	2.0	24
87	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	0.6	24
88	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
89	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021, 5, 861-871.	2.5	23
90	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 4113-4123.	2.5	22

#	ARTICLE	IF	CITATIONS
91	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015, 10, e0132564.	1.1	22
92	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	0.6	21
93	Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. <i>Expert Review of Hematology</i> , 2020, 13, 519-532.	1.0	20
94	Immune reconstitution: The major barrier to successful stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 43-45.	2.0	19
95	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2084-2091.	2.0	16
96	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. <i>Blood Advances</i> , 2017, 1, 2269-2279.	2.5	16
97	Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. <i>Respiratory Research</i> , 2019, 20, 15.	1.4	16
98	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 1881-1893.	2.5	16
99	Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 990.e1-990.e7.	0.6	16
100	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	1.7	15
101	Positive psychological experiences in allogeneic hematopoietic stem cell transplantation. <i>Psycho-Oncology</i> , 2019, 28, 1633-1639.	1.0	15
102	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	1.3	15
103	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	1.7	15
104	Adoptive Immunotherapy for Relapsed Leukemia Following Allogeneic Bone Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1995, 17, 191-197.	0.6	14
105	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. <i>American Journal of Hematology</i> , 2016, 91, 793-799.	2.0	14
106	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 529-539.	2.0	14
107	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020, 135, 28-40.	0.6	14
108	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13

#	ARTICLE	IF	CITATIONS
109	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.	0.3	13
110	A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease. <i>Blood</i> , 1998, 92, 4066-4071.	0.6	13
111	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	0.6	13
112	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	2.5	12
113	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	0.6	12
114	Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies. <i>Blood</i> , 2020, 136, 38-39.	0.6	12
115	The Utility of Routine Chest Radiography in the Initial Evaluation of Adult Patients With Febrile Neutropenia Patients Undergoing HSCT. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 184-189.	2.3	11
116	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. <i>Human Mutation</i> , 2021, 42, 1367-1383.	1.1	11
117	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
118	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	1.4	10
119	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
120	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1272-1276.	2.5	9
121	Targeting PI3K $\hat{\imath}$ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	2.6	9
122	Approaches to graft-vs-host disease. <i>Pediatric Transplantation</i> , 2005, 9, 71-75.	0.5	8
123	Mixed Chimerism Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease Prevents Intravascular Hemolysis and Restores Endothelial Function.. <i>Blood</i> , 2004, 104, 1679-1679.	0.6	8
124	Emerging drugs for graft-versus-host disease. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 209-218.	1.0	7
125	Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 113-118.	2.0	6
126	Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 508.e1-508.e8.	0.6	6

#	ARTICLE	IF	CITATIONS
127	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021, 35, 1166-1175.	3.3	5
128	Survival Following Etanercept Therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 354-354.	0.6	5
129	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. <i>Blood</i> , 2015, 126, 2018-2018.	0.6	5
130	A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 860-860.	0.6	5
131	Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3069-3069.	0.6	5
132	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 667-667.	0.6	4
133	Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial. <i>Blood</i> , 2020, 136, 8-9.	0.6	4
134	Donor leukocyte infusions and graft-versus-malignancy. <i>Journal of Clinical Apheresis</i> , 2005, 20, 113-116.	0.7	3
135	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2164-2165.	2.0	3
136	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e94-e100.	2.0	3
137	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. <i>Blood</i> , 2004, 104, 351-351.	0.6	3
138	Pre-Infusion Characteristics of the Predominant Cord Blood Unit Correlate with Hematopoietic Engraftment in the Setting of Non-Myeloablative Double Cord Blood Transplant (DCBT).. <i>Blood</i> , 2005, 106, 3027-3027.	0.6	3
139	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 835-835.	0.6	3
140	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. <i>Blood</i> , 2016, 128, 66-66.	0.6	3
141	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	0.6	3
142	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	0.6	3
143	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016, 128, 508-508.	0.6	3
144	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2021, 138, 264-264.	0.6	3

#	ARTICLE	IF	CITATIONS
145	The Pathophysiology of Graft-Versus-Host Disease. , 0, , 208-221.		2
146	Effect of Antithymocyte Globulin Source on Outcomes of Bone Marrow Transplantation for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S27.	2.0	2
147	Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1844-1846.	1.3	2
148	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1834-1834.	0.6	2
149	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. <i>Blood</i> , 2004, 104, 2251-2251.	0.6	2
150	Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 595-595.	0.6	2
151	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 387-387.	0.6	2
152	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 69-69.	0.6	2
153	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. <i>Blood</i> , 2004, 104, 300-300.	0.6	2
154	Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic Myelogenous Leukemia.. <i>Blood</i> , 2009, 114, 3316-3316.	0.6	2
155	A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy. <i>Blood</i> , 2017, 130, 678-678.	0.6	2
156	Response to Helsby and Tingle. <i>American Journal of Hematology</i> , 2011, 86, 384-384.	2.0	1
157	Relationship Between Intestinal Bacteria and the Anticancer Effect of Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 1636-1637.	0.8	1
158	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006, 108, 259-259.	0.6	1
159	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. <i>Blood</i> , 2006, 108, 2929-2929.	0.6	1
160	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).. <i>Blood</i> , 2006, 108, 3148-3148.	0.6	1
161	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2006, 108, 3680-3680.	0.6	1
162	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007, 110, 166-166.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. Blood, 2007, 110, 2016-2016.	0.6	1
164	Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).. Blood, 2007, 110, 3046-3046.	0.6	1
165	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. Blood, 2015, 126, 2022-2022.	0.6	1
166	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. Blood, 2015, 126, 737-737.	0.6	1
167	Homeostatic Reconstitution of CD4+ Regulatory and Conventional T Cell Subsets in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2014, 124, 2496-2496.	0.6	1
168	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. Blood, 2020, 136, 10-11.	0.6	1
169	Reply to J. Mehta. Journal of Clinical Oncology, 2009, 27, e139-e140.	0.8	0
170	Secondary Anemias Associated with Hematopoietic Stem Cell Transplantation. , 0, , 179-184.		0
171	The Y-Specific Gene PRY Is Expressed in Normal Blood Cells as Well as Leukemia Cells and Can Elicit a Specific Antibody Response in Male Recipients of Hematopoietic Stem Cells from Female Donors.. Blood, 2004, 104, 4976-4976.	0.6	0
172	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	0.6	0
173	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	0.6	0
174	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. Blood, 2004, 104, 296-296.	0.6	0
175	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. Blood, 2004, 104, 3317-3317.	0.6	0
176	Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.. Blood, 2005, 106, 2051-2051.	0.6	0
177	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. Blood, 2005, 106, 1797-1797.	0.6	0
178	Efficacy of Performing a Second Non-Myeloablative Allogeneic Stem Cell Transplant.. Blood, 2005, 106, 3664-3664.	0.6	0
179	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. Blood, 2006, 108, 2977-2977.	0.6	0
180	Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2006, 108, 757-757.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Non-Myeloablative Allogeneic Transplantation for Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. Blood, 2007, 110, 3041-3041.	0.6	0
182	Factor VIII Is a Potential Autosomal B Cell Minor Histocompatibility Antigen in Chronic Gvhd.. Blood, 2009, 114, 1167-1167.	0.6	0
183	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. Blood, 2011, 118, 3009-3009.	0.6	0
184	Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,. Blood, 2011, 118, 3671-3671.	0.6	0
185	Does Iron Overload Really Matter in Stem Cell Transplantation?. Blood, 2011, 118, 3029-3029.	0.6	0
186	A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 327-327.	0.6	0
187	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1892-1892.	0.6	0
188	Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 4136-4136.	0.6	0
189	SNP-Based Bayesian Networks Define Oral Mucositis Risk in Patients Receiving Stomatotoxic Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 735-735.	0.6	0
190	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. Blood, 2015, 126, 1304-1304.	0.6	0
191	The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma. Blood, 2015, 126, 2007-2007.	0.6	0
192	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. Blood, 2016, 128, 63-63.	0.6	0
193	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 3425-3425.	0.6	0
194	Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 987-987.	0.6	0
195	Defibrotide: Real World Experience for Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 23-24.	0.6	0
196	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. Blood, 2020, 136, 21-22.	0.6	0
197	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 2-3.	0.6	0
198	Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution. Blood, 2020, 136, 12-13.	0.6	0